Market revenue in 2023 | USD 78.8 million |
Market revenue in 2030 | USD 192.7 million |
Growth rate | 13.6% (CAGR from 2023 to 2030) |
Largest segment | Kallikrein inhibitor |
Fastest growing segment | Kallikrein inhibitor |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others Treatment |
Key market players worldwide | BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, CSL Ltd, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Pharming Group, Attune Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.
Kallikrein inhibitor was the largest segment with a revenue share of 44.8% in 2023. Horizon Databook has segmented the Spain hereditary angioedema therapeutics market based on c1-esterase inhibitor, bradykinin b2 receptor antagonist, kallikrein inhibitor, others treatment covering the revenue growth of each sub-segment from 2018 to 2030.
Spain's pharmaceutical sector has continued to receive major investments, which is anticipated to positively influence the hereditary angioedema therapeutics market. The country's supportive healthcare policies & initiatives to increase public awareness and monitor the disease rate are expected to increase the demand for HAE drugs in the market.
According to the Global Competitiveness 2020 Report, the World Economic Forum placed Spain with the world's best healthcare system. The Spanish healthcare system offers its citizens both public and private healthcare alternatives.
The National Health System, managed by the Spanish Ministry of Health, is responsible for developing policies and maintaining the national health budget. It provides free healthcare services to anyone living and working in Spain.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain hereditary angioedema therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Spain hereditary angioedema therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account